Podcast appearances and mentions of max bronstein

In this episode, Sam sits down with Max Bronstein, a leader in biopharmaceutical innovation and health policy, to discuss the future of healthcare. From expanding access to genomic technologies to rethinking drug development models, Max shares insights from his work at the White House Office of Science and Technology Policy and beyond. They explore the challenges of scaling solutions for unmet medical needs, the promise of public-private collaborations, and preparing for the next wave of transformative healthcare innovations.

The growth in skepticism about science that was fueled by disinformation during the pandemic has been a frequent topic on Raise the Line, with many insightful guests from medicine and academia offering analysis of the problem and possible solutions. On today's episode, we'll hear from someone who is very well-placed to actually make progress on this front. Max Bronstein, the Assistant Director for Health Innovation at the White House Office of Science and Technology Policy, joins host Shiv Gaglani to discuss the broad support President Biden has provided for science – elevating his science advisor to the cabinet level being a prime example – and also provide details about programmatic investments that tell the tale at a deeper level. At the top of Bronstein's list of examples is the launch of the Advanced Research Projects Agency for Health, also known as ARPA-H, which aims to drive transformative biomedical and health breakthroughs with a focus on equity. “The mission is about making sure there are cures for diseases, better diagnostic platforms and better technologies out there, but also making sure those are actually available to all Americans.” Don't miss this inside look at new efforts to strengthen the biotechnology workforce, broaden access to clinical genetic sequencing, advance development of treatments for rare diseases, and much more as a new era in health innovation gets underway.  Mentioned in this episode: https://www.whitehouse.gov/ostp/

The latest Long Read is "Crypto Dollars and the Evolution of Eurodollar Banking" by Avi Felman and Max Bronstein.  This piece covers: The Dollar Milkshake Theory Why the demand for the US dollar remains so high  Why demand for dollars is increasing rather than decreasing  What "eurodollars" are What the shadow banking system is How eurodollars and shadow banking contribute to USD demand How stablecoins and cryptodollarization could create demand for crypto 

On the EthHub Weekly Recap we cover topics from the EthHub Weekly Newsletter. In this episode we discuss the Scaling Ethereum workshop, the hunt for an Ethereum mixer, more Facebook stablecoin news, StarkDEX demos speed for 0x, Rocket Pool gives a dev update, Uniswap releases some improvements, DeFi Pulse adds value locked in ETH and a deep dive by Max Bronstein on Dai. Support our show! Get on the email list at ethhub.substack.com

Host Tom Shaughnessy of Delphi Digital (www.DelphiDigital.io) is joined by Max Bronstein of the Dharma Protocol. Dharma enables users to instantly borrow and lend crypto-assets in high volume. This is a two-part DeFi series, stay tuned for part 2 next week.    Follow Tom on Twitter @Shaughnessy119 Follow Max on Twitter @max_bronstein    Disclosure: Tom Shaughnessy owns tokens in ETH, DCR, MKR, ZRX and HYDRO. This podcast is NOT investment advice and is only informational. Do not make investment decisions based upon this podcast. Delphi Digital was not compensated by any party for this podcast episode other than Podbean's advertisers. This content is strictly informational.  - Advertisers: To advertise on this podcast, email Tom@DelphiDigital.io Potential Guests: If you're interested in appearing on the podcast, email Tom@DelphiDigital.io  - 

Max Bronstein comes on to POV Crypto to talk about a whole myriad of topics!   DeFi early days Early Financial Services mechanisms on Ethereum Dharma involvement with the DeFi meme What drives Bitcoin adoption The qualities of Bitcoin vs qualities of Cryptocurrency Credit and Debt and Dharma Shitcoinery? David Defends Spankchain Token Model   Discuss Bitcoin lightning development, expectations, fears, and more.   Please rate and share the podcast! You  can find us @POVCryptopod on Twitter. David Hoffman on Twitter and Medium @trustless_state Christian Keroles on Twitter @ck_SNARKs  [Guest] Max Bronstein  @Max_Bronstein Send Bitcoin: 3P1kkSBdsc2vPWXin3h6bdVeTS4BzXdNG1 Send Ether: 0xa6daaa2c423e72f7a248e1642b0b0151a0ce3778

Legislation that would provide incentives to drugmakers to repurpose existing pharmaceuticals as rare disease treatments is once again in the works. Known as The OPEN ACT (Orphan Product Extensions Now, Accelerating Cures and Treatments), proponents say it would help address a gap in the drug development landscape. At one point, the bill had been folded into the 21st Century Cures Act, but had been stripped out before passage. We spoke to Max Bronstein, chief advocacy and science policy officer for the Everylife Foundation for Rare Diseases, about the legislation, why its needed, and what it will take to get passed.

For our second interview before Rare Disease Day (Feb 28), we chat with Max Bronstein, Chief Advocacy and Science Policy Officer at The Everylife Foundation for Rare Diseases. The goal of the Foundation is to help advance innovation in the rare disease community; to advance knowledge and methods of support for those with a rare disease, and to ultimately look towards developing and enabling access to treatments or cures. Max is a scientist at heart; he has been published in Nature and The New England Journal of Medicine which makes him a great ally in raising awareness of rare diseases. He uses his background in his job at The Everylife Foundation in two big ways. One way that he uses his science background is what he calls regulatory issues. He does this by continuously holding meetings with large health and biotech and pharma partners. He speaks directly to the doctors and scientists at the forefront of cutting edge research in health and medicine and reminds them of the reality of rare diseases, a field often overlooked or forgotten. Another way that Max is a voice for those in the rare disease community is by working in social policy issues. This is when Max sets up meetings with politicians so that the rare disease community is represented. This involves dialoguing with senators and representatives on Capitol Hill whenever drug costs, talks of healthcare, or any other issue related to the rare disease community arises, and also just to meet with them regularly to remind them of the reality of rare diseases. He regularly goes to both the White House and Congress. Max explains these to us and walks us through a big success that The Everylife Foundation and other organizations helped push through instituted: the 21st Century Cures Act. Keep in touch with The Everylife Foundation to keep up with all of their diverse efforts and  find out how you can get involved! Visit their website at http://everylifefoundation.org/, follow them on Facebook: https://www.facebook.com/EveryLife4RareDiseases/, and Twitter: @EveryLifeOrg.

  "We have a big innovation gap in this country when it comes to rare disease therapies. 7,000 diseases and only roughly 300 treatments on the market for those diseases. We have a long way to go and there's a lot of work that needs to be done if we ever want to get to the point where we have one treatment for all of those diseases or even multiple treatments - and that is what our foundation is set up and designed to do." For our second interview before Rare Disease Day (Feb 28), we chat with Max Bronstein, Chief Advocacy and Science Policy Officer at The Everylife Foundation for Rare Diseases. The goal of the Foundation is to help advance innovation in the rare disease community; to advance knowledge and methods of support for those with a rare disease, and to ultimately look towards developing and enabling access to treatments or cures.   Max is a scientist at heart; he has been published in Nature and The New England Journal of Medicine which makes him a great ally in raising awareness of rare diseases. He uses his background in his job at The Everylife Foundation in two big ways.   One way that he uses his science background is what he calls regulatory issues. He does this by continuously holding meetings with large health and biotech and pharma partners. He speaks directly to the doctors and scientists at the forefront of cutting edge research in health and medicine and reminds them of the reality of rare diseases, a field often overlooked or forgotten.   Another way that Max is a voice for those in the rare disease community is by working in social policy issues. This is when Max sets up meetings with politicians so that the rare disease community is represented. This involves dialoguing with senators and representatives on Capitol Hill whenever drug costs, talks of healthcare, or any other issue related to the rare disease community arises, and also just to meet with them regularly to remind them of the reality of rare diseases. He regularly goes to both the White House and Congress.   Max explains these to us and walks us through a big success that The Everylife Foundation and other organizations helped push through instituted: the 21st Century Cures Act. Keep in touch with The Everylife Foundation to keep up with all of their diverse efforts and  find out how you can get involved! Visit their website at http://everylifefoundation.org, and follow them on Facebook: https://www.facebook.com/EveryLife4RareDiseases/, and Twitter: @EveryLifeOrg.

In the rare disease community, strength is in unity and supporting one another. February 28th is globally recognized as Rare Disease Day. Since Friedreich's ataxia, the disease shared by us  Dudes, is considered a rare disease, five episodes will come out in February, instead of one episode every other week, as normal. We explain what is meant by “rare diseases” and how rare they really are. This episode contains snippets of three interviews that will be released in their entirety later in the month. Nicole Boice, the CEO of Global Genes, speaks about the importance of knowledge in the rare disease community; only by knowing all we can about whatever disorder we may face can we successfully move forward. In the second snippet, Max Bronstein of the Everylife Foundation for Rare Diseases reminds us of the importance of policy issues when seeking treatments for rare diseases. Finally Paul Melmeyer from the National Organization of Rare Disorders (NORD) emphasizes the benefits of recognizing Rare Disease Day, and what that has done for the rare disease community overall. On February 27, the day before Rare Disease Day, our interview with Ron Bartek, the president and cofounder of the Friedreich's Ataxia Research Alliance, will be released. The Two Disabled Dudes invite you to help us spread awareness this month.

In the rare disease community, strength is in unity and supporting one another. Image courtesy of debra February 28th is globally recognized as Rare Disease Day. Since Friedreich’s ataxia (FA), the disease shared by us Dudes, is considered a rare disease, five episodes will come out in February, instead of one episode every other week, as normal.   In this episode we talk about what is meant by “rare diseases” and how rare they really are. This episode contains snippets of three interviews that will be released in their entirety later in the month. Nicole Boice, the CEO of Global Genes, speaks about the importance of knowledge in the rare disease community; only by knowing all we can about whatever disorder we may face can we successfully move forward. In the second snippet, Max Bronstein of the Everylife Foundation for Rare Diseases reminds us of the importance of policy issues when seeking treatments for rare diseases. Finally Paul Melmeyer from the National Organization of Rare Disorders (NORD) emphasizes the benefits of recognizing Rare Disease Day, and what that has done for the rare disease community overall.   On February 27, the day before Rare Disease Day, our interview with Ron Bartek, President and co-founder of the Friedreich’s Ataxia Research Alliance, will be released.   The Two Disabled Dudes invite you to help us spread awareness this month.   Organizations Highlighted in This Episode:   Global Genes - globalgenes.org   EveryLife Foundation for Rare Diseases - everylifefoundation.org   National Organization for Rare Disorders - rarediseases.org   Friedreich's Ataxia Research Alliance (FARA) - curefa.org

The 21st Century Cures Act, an ambitious piece of legislation of great concern to the rare disease community, passed the House last year only to stall the Senate. Now it’s back on the radar. The legislation is moving forward again, but this time in pieces. Separately in California, proposed legislation can greatly accelerate the process that tests are added to the list of newborn screening diagnostics that are performed. We spoke to Max Bronstein, senior director of public and government relations for the Everylife Foundation for Rare Diseases, about the developments on the legislative front, what the outlook is, and why these issues matter to the rare disease community.

The rare disease community in July celebrated the passage in the House of the 21st Century Cures Act, legislation that promises among other things to accelerate the development of drugs to treat rare diseases. But the legislation appears to be stalled in the Senate as the clock is running and concern growing that it may not be getting the attention it needs to push it across the finish line. We spoke to Max Bronstein, senior director of public and government relations for the Everylife Foundation for Rare Diseases, about the legislation, where it stands today, and what it will take to see it become law.